血管瘤和脉管畸形的诊疗进展（2018—2019）及关键性问题

doi:10.19438/j.cjoms.2019.06.002

摘要/Abstract

摘要： 本文总结了2018年1月—2019年3月在血管瘤和脉管畸形领域的进展,从引人注目的ISSVA 2018阿姆斯特丹会议上提出的分类修改,到各类血管瘤和脉管畸形的每个主要分类的点滴进展,分别涉及病因、标志物、基础研究到早期诊断、鉴别诊断和治疗、遗传学、精准治疗等最近的新观点和创新实践。列举这些我们亦参与其中的进展,旨在分析和预测本领域未来发展的方向,更快造福于血管瘤和脉管畸形患者。

关键词: 血管瘤, 脉管畸形, 脉管性疾病, 进展, 诊断, 治疗

Abstract: We briefly reviewed the most significant advances in the field of vascular anomalies,from January 2018 to March 2019, which have been published recently and ISSVA Workshop in 2018, updating the classification, diagnosis, differential diagnosis, and treatment of vascular anomalies,including surgical treatment, endovascular therapies, laser treatment and drug therapies. We also introduced the breakthroughs in basic research, genetic discoveries and animal model development, and expounded on our predictions of the proposed future to help shaping this field.

Key words: Hemangioma, Vascular malformation, Vascular anomalies, Advances, Diagnosis, Treatment

中图分类号:

R739.8

林晓曦. 血管瘤和脉管畸形的诊疗进展（2018—2019）及关键性问题[J]. 中国口腔颌面外科杂志, 2019, 17(6): 486-495.

LIN Xiao-xi. What is new in vascular anomalies: the updates from 2018 to 2019[J]. China J Oral Maxillofac Surg, 2019, 17(6): 486-495.

参考文献

[1] Byun JW, AnHY, Yeom SD, et al. NDRG1 and FOXO1 regulate endothelial cell proliferation in infantile haemangioma[J]. Exp Dermatol, 2018, 27(6): 690-693.
[2] Oszajca K, Szemraj J, Wyrzykowski D, et al.Single-nucleotide polymorphisms of VEGF-A and VEGFR-2 genes and risk of infantile hemangioma[J]. Int J Dermatol, 2018, 57(10): 1201-1207.
[3] Yin RR, Hao D, Chen P.Expression and correlation of MMP-9, VEGF, and p16 in infantile hemangioma[J]. Eur Rev Med Pharmacol Sci, 2018, 22(15): 4806-4811.
[4] Huang C, Huang J, Yu G.Co-suppression of VEGF-A and VEGF-C inhibits development of experimental hemangioma[J]. Am J Transl Res, 2018, 10(9): 2911-2919.
[5] Yamashita T, Jinnin M, Makino K, et al.Serum cytokine profiles are altered in patients with progressive infantile hemangioma[J]. Biosci Trends, 2018, 12(4): 438-441.
[6] El-Raggal NM, El-Farrash RA, Saad AA, et al.Circulating levels of vascular endothelial growth factor and basic fibroblastic growth factor in infantile hemangioma versus vascular malformations[J]. Clin Appl Thromb Hemost, 2018, 24(4): 663-668.
[7] Lou S, Wang Y, Yu Z, et al.Curcumin induces apoptosis and inhibits proliferation in infantile hemangioma endothelial cells via downregulation of MCL-1 and HIF-1 alpha[J]. Medicine (Baltimore), 2018, 97(7): e9562.
[8] Yao TH, Pataer P, Regmi KP, et al.Propranolol induces hemangioma endothelial cell apoptosis via a p53BAX mediated pathway[J]. Mol Med Rep, 2018,18(1): 684-694.
[9] Lin Z, Wang L, Huang G, et al.Propranolol inhibits the activity of PI3K, AKT, and HIF-1alpha in infantile hemangiomas[J]. Pediatr Surg Int, 2018, 34(11): 1233-1238.
[10] Sun B, Dong C, Lei H, et al.Propranolol inhibits proliferation and invasion of hemangioma-derived endothelial cells by suppressing the DLL4/Notch1/Akt pathway[J]. Chem Biol Interact, 2018, 294(1): 28-33.
[11] Mong EF, Akat KM, Canfield J, et al.Modulation of LIN28B/Let-7 signaling by propranolol contributes to infantile hemangioma involution[J]. Arterioscler Thromb Vasc Biol, 2018,38(6): 1321-1332.
[12] Xu W, Li S, Yu F, et al.Role of thrombospondin-1 and nuclear factor-kappa B signaling pathways in anti-angiogenesis of infantile hemangioma[J]. Plast Reconstr Surg, 2018,142(3):310e-321e.
[13] 张永婷,徐伟立,李索林,等. TSP-1与NF-κB通路蛋白在婴幼儿毛细血管瘤中的表达[J].中华整形外科杂志,2016,32(6):441-446.
[14] Laurens C, A Abot, A Delarue, et al. Central effects of beta-blockers may be due to nitric oxide and hydrogen peroxide release independently of their ability to cross the blood-brain barrier[J]. Front Neurosci, 2019,13: 33.
[15] Kagami S, Katori T.Oral propranolol for infantile hemangiomas beyond the proliferative phase[J]. J Dermatol, 2018, 45(10): 1199-1202.
[16] Kagami S, Kaneko M, Kishi A, et al.Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment[J]. J Dermatol, 2018,45(9): 1109-1112.
[17] Polites SF, Rodrigue BB, Chute C, et al.Propranolol versus steroids for the treatment of ulcerated infantile hemangiomas[J]. Pediatr Blood Cancer, 2018, 65(10): e27280.
[18] Frongia G, Byeon JO, Arnold R, et al.Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants[J]. World J Pediatr, 2018, 14(3): 254-258.
[19] Lou H, Xu G, Huo R.Curative effect and safety of propranolol combined with prednisone in the treatment of infantile hemangiomas[J]. Exp Ther Med, 2018,15(6): 4677-4682.
[20] Chang L, Lv D, Yu Z, et al.Infantile hemangioma: factors causing recurrence after propranolol treatment[J]. Pediatr Res, 2018, 83(1-1): 175-182.
[21] Chang L, Chen H, Yang X, et al.Intralesional bleomycin injection for propranolol-resistant hemangiomas[J]. J Craniofac Surg, 2018,29(2): e128-e130.
[22] Ginguerra MA, Saito O, Fernandes J, et al.Clinical and radiological evaluation of periocular infantile hemangioma treated with oral propranolol: a case series[J]. Am J Ophthalmol, 2018,185(1): 48-55.
[23] Li L, Wei L, Xu ZG, et al.No increased risks associated with propranolol treatment for infantile hemangioma in preterm infants were identified at 3 years of age[J]. Am J Clin Dermatol, 2019,20(2): 289-293.
[24] Wang Q, Xiang B, Chen S, et al.Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review[J]. Australas J Dermatol, 2019,60(3):181-185.
[25] Thai T, Wang CY, Chang CY, et al. Central nervous system effects of oral propranolol for infantile hemangioma: a systematic review and meta-analysis [J]. J Clin Med, 2019, 8(2). pii: E268.
[26] Baselga E, Dembowska-Baginska B, Przewratil P, et al. Efficacy of propranolol between 6 and 12 months of age in high-risk infantile hemangioma[J]. Pediatrics, 2018, 142(3). pii: e20173866.
[27] Polites SF, Watanabe M, Crafton T, et al.Surgical resection of infantile hemangiomas following medical treatment with propranolol versus corticosteroids[J]. J Pediatr Surg, 2019, 54(4): 740-743.
[28] Waner M.The surgical management of infantile hemangiomas[J]. Otolaryngol Clin North Am, 2018,51(1): 125-131.
[29] Hochman M.The role of surgery in the management of infantile hemangiomas: what is the best timing?[J]. Otolaryngol Clin North Am, 2018,51(1): 119-123.
[30] Dalla Costa R, Prindaville B, Wiss K.Doing the math: A simple approach to topical timolol dosing for infantile hemangiomas[J]. Pediatr Dermatol, 2018,35(2): 276-277.
[31] Borok J, Gangar P, Admani S, et al.Safety and efficacy of topical timolol treatment of infantile haemangioma: a prospective trial[J]. Br J Dermatol, 2018, 178(1): e51-e52.
[32] Gan LQ, Wang H, Ni SL, et al.A prospective study of topical carteolol therapy in Chinese infants with superficial infantile hemangioma[J]. Pediatr Dermatol, 2018,35(1): 121-125.
[33] He L, Huang G.Spectral Doppler ultrasound for predicting long-term response to topical timolol in children with infantile hemangioma[J]. J Clin Ultrasound, 2017,45(8): 480-487.
[34] Ng MSY, Tay YK, Ng SS, et al.Comparison of two formulations of topical timolol for the treatment of infantile hemangiomas[J]. Pediatr Dermatol, 2017,34(4): 492-493.
[35] Gummi R, Stahl ED, Marsh JD.Topical timolol for an iris hemangioma[J]. J AAPOS, 2018,22(2): 156-158.
[36] Zheng L, Li Y.Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta-analysis[J]. Arch Dermatol Res, 2018,310(4): 261-269.
[37] Zeng M, Shen S, Chen W, et al.Superficial hemangioma is better treated by topical 5-aminolevulinic followed by 595-nm pulsed dye laser therapy rather than 595-nm laser therapy alone[J]. Lasers Med Sci, 2017,32(8): 1889-1893.
[38] O'Brien KF, Shah SD, Pope E, et al. Late growth of infantile hemangiomas in children >3 years of age: A retrospective study[J]. J Am Acad Dermatol, 2019,80(2): 493-499.
[39] Valdivielso-Ramos M, Torrelo A, Martin-Santiago A, et al.Infantile hemangioma with minimal or arrested growth as the skin manifestation of PHACE syndrome[J]. Pediatr Dermatol, 2018,35(5): 622-627.
[40] Samuelov L, Kinori M, Mancini AJ, et al.Ocular complications in PHACE syndrome: a true association or a coincidence?[J]. J Pediatr, 2019, 204: 214-218.
[41] Mamlouk MD, Zimmerman B, Mathes EF, et al.Hearing loss in PHACE syndrome: clinical and radiologic findings[J]. Childs Nerv Syst, 2018,34(9): 1717-1724.
[42] McCormick AA, Tarchichi T, Azbell C, et al. Subglottic hemangioma: Understanding the association with facial segmental hemangioma in a beard distribution[J]. Int J Pediatr Otorhinolaryngol, 2018,113(1): 34-37.
[43] Steiner JE, McCoy GN, Hess CP, et al. Structural malformations of the brain, eye, and pituitary gland in PHACE syndrome[J]. Am J Med Genet A, 2018,176(1): 48-55.
[44] Demartini Z Jr, Gatto LAM, Lages RO, et al.Atypical presentation of PHACE syndrome: hidden facial hemangioma[J]. Pediatr Neurosurg, 2018,53(6): 421-426.
[45] Siegel DH.PHACE syndrome: Infantile hemangiomas associated with multiple congenital anomalies: Clues to the cause[J]. Am J Med Genet C Semin Med Genet, 2018, 178(4): 407-413.
[46] Burleigh A, Kanigsberg N, Lam JM.Topical rapamycin (sirolimus) for the treatment of uncomplicated tufted angiomas in two children and review of the literature[J]. Pediatr Dermatol, 2018,35(5): e286-e290.
[47] Russell TB, Rinker EK, Dillingham CS, et al.Pneumocystis jirovecii pneumonia during sirolimus therapy for Kaposiform hemangioendothelioma[J]. Pediatrics, 2018,141(Suppl 5): S421-S424.
[48] Schmid I, Klenk AK, Sparber-Sauer M, et al.Kaposiform hemangioendothelioma in children: a benign vascular tumor with multiple treatment options[J]. World J Pediatr, 2018,14(4): 322-329.
[49] Ji Y, Yang K, Peng S, et al.Kaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach-Merritt phenomenon[J]. Br J Dermatol, 2018,179(2): 457-463.
[50] Ji Y, Yang K, Chen S, et al.Musculoskeletal complication in kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon: clinical characteristics and management[J]. Cancer Manag Res, 2018,10: 3325-3331.
[51] Xing L, Chen B, Li D, et al.Gold nanospheres enhanced photothermal therapy in a rat model[J]. Lasers Surg Med, 2018, doi: 10.1002/lsm.22793.
[52] Rodriguez-Laguna L, Ibanez K, Gordo G, et al.CLAPO syndrome: identification of somatic activating PIK3CA mutations and delineation of the natural history and phenotype[J]. Genet Med, 2018,20(8): 882-889.
[53] Yu W, Zhu J, Changc SJ, et al.Shorter treatment intervals of east Asians with port-wine stain with pulsed dye laser are safe and effective-a prospective side-by-side comparison[J]. Photomed Laser Surg, 2018,36(1): 37-43.
[54] Wang T, Chen D, Yang J, et al.Safety and efficacy of dual-wavelength laser (1064 + 595 nm) for treatment of non-treated port-wine stains[J]. J Eur Acad Dermatol Venereol, 2018,32(2): 260-264.
[55] Yu W, Zhu J, Gu Y, et al.Port-wine stains on the neck respond better to a pulsed dye laser than lesions on the face: An intrapatient comparison study with histopathology[J]. J Am Acad Dermatol, 2019,80(3): 779-781.
[56] Doh EJ, Ohn J, Kim MJ, et al.Prospective pilot study on combined use of pulsed dye laser and 1% topical rapamycin for treatment of nonfacial cutaneous capillary malformation[J]. J Dermatolog Treat, 2017,28(7): 672-677.
[57] Musalem HM, Alshaikh AA, Tuleimat LM, et al.Outcome with topical sirolimus for port wine stain malformations after unsatisfactory results with pulse dye laser treatment alone[J]. Ann Saudi Med, 2018,38(5): 376-380.
[58] Alcantara-Gonzalez J, Boixeda P, Truchuelo-Diez MT, et al.Capillary malformations treated with sequential pulsed dye and Nd:YAG laser therapy: a retrospective study[J]. Actas Dermosifiliogr, 2018,109(2): 155-161.
[59] Yu W, Wang T, Zhu J, et al.EMLA cream does not influence efficacy and pain reduction during pulsed-dye laser treatment of port-wine stain: a prospective side-by-side comparison[J]. Lasers Med Sci, 2018,33(3): 573-579.
[60] Sari E and B Bakar. Which is more effective for pain relief during fractionated carbon dioxide laser treatment: EMLA cream or forced cold air anesthesia?[J]. J Cosmet Laser Ther, 2018, 20(1): 34-40.
[61] Gao L, Qian L, Wang L, et al.Topical halometasone reduces acute adverse effects induced by pulsed dye laser for treatment of port wine stain birthmarks[J]. J Lasers Med Sci, 2018,9(1): 19-22.
[62] Pushkareva AE, Ponomarev IV, Topchiy SB, et al.Comparative numerical analysis and optimization of blood vessels heated using various lasers[J]. Laser Physics, 2018,28(9): 096003.
[63] Ma J, Chen B, Li D, et al.Correction to: glucose in conjunction with multiple laser pulses on laser treatment of port-wine stain: an in vivo study[J]. Lasers Med Sci, 2018,33(9): 2015.
[64] Pan ZY, Dong DK, Chen SJ, et al.In vivo reflectance confocal microscopy in daily practice: Image features correlated to histopathology[J]. Skin Res Technol, 2018, 24(2): 223-228.
[65] van Raath MI, Bambach CA, Dijksman LM, et al. Prospective analysis of the port-wine stain patient population in the Netherlands in light of novel treatment modalities[J]. J Cosmet Laser Ther, 2018, 20(2): 77-84.
[66] Lai Y, Zhang H, Wei M, et al.Can red-light 5-aminolevulinic photodynamic therapy cure port wine stains on comb animal model?[J]. Photodiagnosis Photodyn Ther, 2018,22: 253-262.
[67] Li-Qiang G, Hua W, Si-Li N, et al.A clinical study of HMME-PDTtherapy in Chinese pediatric patients with port-wine stain[J]. Photodiagnosis Photodyn Ther, 2018,23: 102-105.
[68] Wu Q, Tu P, Zhou G, et al.A dose-finding study for hemoporfin in photodynamic therapy for port-wine stain: A multicenter randomized double-blind phase IIb trial[J]. Photodermatol Photoimmunol Photomed, 2018,34(5): 314-321.
[69] Ma G, Han Y, Wu P, et al.478 Comparison of two generation photosensitizers of PsD-007 and HMME photodynamic therapy for treatment of port-wine stain: A retrospective study[J]. J Invest Dermatoly, 2018,138(5, Supplement): S81.
[70] 姚翠萍,王佳壮,王晶,等.Au@TiO₂纳米核壳与HMME结合体的制备及其光动力疗效观察[J].光谱学与光谱分析,2017,37(12):3670-3676.
[71] Ma J, Lai G, Lu Z.Effect of 410 nm photodynamic therapy with hemoporfin on the expression of vascular endothelial growth factor (VEGF) in cultured human vascular endothelial cells[J]. Lasers Med Sci, 2019,34(1): 149-155.
[72] Bichsel CA, Goss J, Alomari M, et al.Association of somatic GNAQ mutation with capillary malformations in a case of choroidal hemangioma[J]. JAMA Ophthalmol, 2019,137(1): 91-95.
[73] Warne RR, Carney OM, Wang G, et al.The bone does not predict the brain in Sturge-Weber syndrome[J]. AJNR Am J Neuroradiol, 2018, 39(8): 1543-1549.
[74] Goines J, Li X, Cai Y, et al.A xenograft model for venous malformation[J]. Angiogenesis, 2018,21(4): 725-735.
[75] Du Z, Ma HL, Zhang ZY, et al.Transgenic expression of a venous malformation related mutation, TIE2-R849W, significantlyinduces multiple malformations of zebrafish[J]. Int J Med Sci, 2018,15(4): 385-394.
[76] Hammer J, Seront E, Duez S, et al.Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study[J]. Orphanet J Rare Dis, 2018,13(1): 191.
[77] Wang KL, Ma SF, Pang LY, et al.Sirolimus alternative to blood transfusion as a life saver in blue rubber bleb nevus syndrome: A case report[J]. Medicine (Baltimore), 2018,97(8): e9453.
[78] Hu L, Chen H, Yang X, et al.Joint dysfunction associated with venous malformations of the limbs: Which patients are at high risk?[J]. Phlebology, 2018,33(2): 89-96.
[79] Hu L, Chen H, Yang X, et al.Risk factors associated with pain in patients with venous malformations of the extremities[J]. Vasc Med, 2019,24(1): 56-62.
[80] Kalin-Hajdu E, Colby JB, Idowu O, et al.Diagnosing distensible venous malformations of the orbit with diffusion-weighted magnetic resonance imaging[J]. Am J Ophthalmol, 2018,189: 146-154.
[81] Brandigi E, Torino G, Messina M, et al.Combined capillary-venous-lymphatic malformations without overgrowth in patients with Klippel-Trenaunay syndrome[J]. J Vasc Surg Venous Lymphat Disord, 2018, 6(2): 230-236.
[82] Binet Q, Lambert C, Hermans C.Dabigatran etexilate in the treatment of localized intravascular coagulopathy associated with venous malformations[J]. Thromb Res, 2018,168: 114-120.
[83] Laurian C, Masonni C, Wassef M, et al.Surgical treatment of venous malformations of the knee: treatment outcomes for 35 patients[J]. J Pediatr Orthop, 2018, 38(6): e325-e331.
[84] Fabian Z, Szabo G, Petrovan C, et al.Intraosseous venous malformation of the zygomatico-orbital complex. Case report and literature review with focus on confusions in vascular lesion terms[J]. Oral Maxillofac Surg, 2018,22(2): 241-247.
[85] Seront E, Vikkula M, Boon LM.Venous malformations of the head and neck[J]. Otolaryngol Clin North Am, 2018,51(1): 173-184.
[86] Chen AW, Liu SH, Huang YY, et al.Preliminary experience with more stable polidocanol foam in sclerotherapy of head and neck venous malformations[J]. Dermatol Surg, 2018,44(11): 1421-1426.
[87] Chewning RH, Monroe EJ, Lindberg A, et al.Combined glue embolization and excision for the treatment of venous malformations[J]. CVIR Endovascular, 2018,1(1): 22.
[88] Gregory S, Burrows PE, Ellinas H, et al.Combined Nd: YAG laser and bleomycin sclerotherapy under the same anesthesia for cervicofacial venous malformations: A safe and effective treatment option[J]. Int J Pediatr Otorhinolaryngol, 2018, 108(1): 30-34.
[89] Then EO, Ofosu A, Rawla P, et al.Klippel-Trenaunay syndrome, a rare cause of hematochezia[J]. Gastroenterology Res, 2018,11(6): 426-429.
[90] Li HB, Zhang J, Li XM, et al.Clinical efficacy of absolute ethanol combined with n-butyl cyanoacrylate sclerotherapy in the treatment of Puig's classified advanced venous malformation in children[J]. Exp Ther Med, 2019,17(2):1276-1281.
[91] Ivars M, Martin-Santiago A, Baselga E, et al.Fern-shaped patch as a hallmark of blue rubber bleb nevus syndrome in neonatal venous malformations[J]. Eur J Pediatr, 2018,177(9): 1395-1398.
[92] Liu D, Li Y, Zhang Y, et al.Volume-staged gamma knife radiosurgery for orbital venous malformations[J]. J Neurosurg, 2018,129(Suppl1): 26-30.
[93] Uller W, Hammer S, Wildgruber M, et al.Radiofrequency ablation of the marginal venous system in patients with venous malformations[J]. Cardiovas Intervent Radiol, 2019,42(2): 213-219.
[94] Zhang G, Chen H, Zhen Z, et al.Sirolimus for treatment of verrucous venous malformation: A retrospective cohort study[J]. J Am Acad Dermatol, 2019,80(2): 556-558.
[95] Kato M, Watanabe S, Iida T, et al.Flow pattern classification in lymphatic malformations by indocyanine green lymphography[J]. Plast Reconstr Surg, 2019,143(3): 558e-564e.
[96] Lagrèze WA, Joachimsen L, Gross N, et al.Sirolimus-induced regression of a large orbital lymphangioma[J]. Orbit, 2019,38(1): 79-80.
[97] Le Sage S, David M, Dubois J, et al.Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: a case series[J]. Pediatr Dermatol, 2018,35(4): 472-477.
[98] Wiegand S, Wichmann G, Dietz A.Treatment of lymphatic malformations with the mTOR inhibitor sirolimus: a systematic review[J]. Lymphat Res Biol, 2018,16(4): 330-339.
[99] Mustak H, Ugradar S, Goldberg R, et al.Bevacizumab and bleomycin combination for treatment of orbital lymphatico‐venous malformation recalcitrant to sclerosing therapy alone[J]. Clin Exp Ophthalmol, 2018,46(7):815-816.
[100] Thomas JM, Surendran S, Abraham M, et al.Gene expression analysis of nidus of cerebral arteriovenous malformations reveals vascular structures with deficient differentiation and maturation[J]. PloS One, 2018,13(6): e0198617.
[101] Vollherbst DF, Otto R, von Deimling A, et al. Evaluation of a novel liquid embolic agent (precipitating hydrophobic injectable liquid (PHIL)) in an animal endovascular embolization model[J]. J Neurointervent Surg, 2018,10(3): 268-274.
[102] Touma J, Dai J, Gaston A, et al.Catheter injected bone marrow mesenchymal stem cells induce efficacious occlusion of arteriovenous nidus in a swine model[J]. Eur J Vasc Endovas Surg, 2018,55(3): 433-442.
[103] Chang L, Lv D, Jin Y, et al.High-frequency color Doppler ultrasound as the first diagnostic and monitoring choice for early superficial high-flow vascular malformations[J]. J Med Ultrason, 2017,44(3): 275-278.
[104] Jin Y, Zou Y, Hua C, et al.Treatment of early-stage extracranial arteriovenous malformations with intralesional interstitial bleomycin injection: a pilot study[J]. Radiology, 2018,287(1): 194-204.
[105] Jin Y, Yang X, Hua C, et al.Ethanol embolotherapy for the management of refractory chronic skin ulcers caused by arteriovenous malformations[J]. J Vasc Interv Radiol, 2018, 29(1): 107-113.
[106] Hua C, Jin Y, Yang X, et al.Midterm and long-term results of ethanol embolization of auricular arteriovenous malformations as first-line therapy[J]. J Vasc Surg, 2018,6(5): 626-635.
[107] Dabus G, Linfante I, Benenati J, et al.Interventional management of high-flow craniofacial vascular malformations: a database analysis and review of the literature[J]. J Neurointervent Surg, 2017,9(1): 92-96.
[108] Kitagawa A, Yamamoto T, Matsunaga N, et al.Polidocanol sclerotherapy combined with transarterial embolization using n-butyl cyanoacrylate for extracranial arteriovenous malformations[J]. Cardiovas Intervent Radiol, 2018, 41(6): 856-866.
[109] Han Y, Fan X, Su L, et al.Absolute ethanol embolization combined with surgical resection of scalp arteriovenous malformations: interim results[J]. J Vasc Interv Radiol, 2018,29(3): 312-319.
[110] Nikolaev SI, Vetiska S, Bonilla X, et al.Somatic activating KRAS mutations in arteriovenous malformations of the brain[J]. N Engl J Med, 2018, 378(3): 250-261.
[111] Wooderchak-Donahue WL, Johnson P, McDonald J, et al. Expanding the clinical and molecular findings in RASA1 capillary malformation-arteriovenous malformation[J]. Eur J Hum Genet, 2018,26(10): 1521-1536.
[112] Cai R, Liu F, Hua C, et al.A novel RASA1 mutation causing capillary malformation-arteriovenous malformation (CM-AVM): the first genetic clinical report in East Asia[J]. Hereditas, 2018,155: 24.
[113] Cai R, F Liu, Q Cen, et al. Capillary malformation in the midline of the face: Salmon patch or port-wine stain?[J]. J Dermatol, 2018,45(11): e317.
[114] Ma G, Yu Z, Liu F, et al.Somatic GNAQ mutation in different structures of port-wine macrocheilia[J]. Br J Dermatol, 2018,179(5): 1109-1114.
[115] Venot Q, Blanc T, Rabia SH, et al.Targeted therapy in patients with PIK3CA-related overgrowth syndrome[J]. Nature, 2018,558(7711):540-546.